封面
市場調查報告書
商品編碼
1661058

醫院獲得性疾病檢測市場報告(按適應症(UTI(泌尿道感染)、SSI(手術部位感染)、肺炎、血流感染、MRSA(耐甲氧西林金黃色葡萄球菌)等)和地區分類,2025 年至 2033 年

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球醫院內疾病檢測市場規模達到 140 億美元。推動市場發展的因素有幾個,包括老年人口的增加、醫院內獲得性感染(HAI)如泌尿道感染(UTI)、血液感染和肺炎的盛行率增加,以及接受各種外科手術的人數不斷增加。

院內感染 (HAI) 或院內感染是在醫院和醫療診所內感染的疾病。院內感染是指在醫院內發生的感染或疾病。即使在療養院、復健中心、醫院或任何其他臨床環境附近,人們也可能感染此類疾病。大多數人在加護病房 (ICU) 和急診室 (ER) 時感染醫院感染。一般來說,這些疾病的潛伏期為患者入院後的48小時至4天。醫院內感染疾病發生的一個主要原因是醫院內部工作人員缺乏適當的衛生習慣。其他原因可能包括維護水準低於標準、醫院工作人員的自滿以及多重抗藥性細菌 (MDRO) 的增加。一些最常見的院內感染包括肺炎、原發性血流感染、泌尿道感染等。當皮膚保護層接觸到可能的威脅並導致感染時,尤其是在手術後,就會發生這種情況。

市場趨勢:

在人口成長和醫療基礎設施現代化的推動下,全球醫療設施的數量顯著增加。這導致醫院感染發生率上升,從而推動了醫院內獲得性疾病檢測的需求。此外,隨著技術的進步和科學創新,市場上已經有各種用於預防、診斷和監測醫院感染的技術,例如微陣列、聚合酶鏈反應(PCR)、即時定位系統(RTLS)和固相雜交。 RTLS 等技術可以輕鬆防止醫院感染在患者和工作人員中傳播。患者對醫院感染認知的不斷增強,以及政府頒布法規對醫院感染發病率高的醫院進行懲罰,這些都是催化市場成長的其他因素。

本報告解答的關鍵問題

  • 2024 年全球醫院內獲得性疾病檢測市場的市場規模是多少? 2025 年至 2033 年全球醫院內獲得性疾病檢測市場的成長如何?
  • 全球醫院內獲得性疾病檢測市場的促進因素有哪些?
  • 全球醫院內獲得性疾病檢測市場的主要行業趨勢是什麼?
  • COVID-19 對全球醫院內獲得性疾病檢測市場有何影響?
  • 全球醫院內獲得性疾病檢測市場按適應症分類的情況如何?
  • 全球醫院內獲得性疾病檢測市場的主要區域有哪些?
  • 全球醫院內感染檢測市場的關鍵公司/參與者有哪些?

目錄

第 1 章:前言

第 2 章:範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章:執行摘要

第 4 章:簡介

  • 概述
  • 主要行業趨勢

第 5 章:全球醫院獲得性疾病檢測市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場區隔:按適應症
  • 市場分佈:按地區
  • 市場預測
  • SWOT 分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價格分析

第6章:市場區隔:依適應症

  • UTI(泌尿道感染)
    • 市場趨勢
    • 市場預測
  • SSI(手術部位感染)
    • 市場趨勢
    • 市場預測
  • 肺炎
    • 市場趨勢
    • 市場預測
  • 血流感染
    • 市場趨勢
    • 市場預測
  • MRSA(抗甲氧西林金黃色葡萄球菌)
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第7章:市場區隔:依地區

  • 北美洲
    • 市場趨勢
    • 市場預測
  • 歐洲
    • 市場趨勢
    • 市場預測
  • 亞太地區
    • 市場趨勢
    • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 市場預測
  • 拉丁美洲
    • 市場趨勢
    • 市場預測

第 8 章:競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • Cepheid, Inc.
Product Code: SR112025A1128

The global hospital acquired disease testing market size reached USD 14.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 49.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15% during 2025-2033. There are several factors that are driving the market, which include the rising geriatric population, increasing prevalence of hospital acquired infections (HAIs) like urinary tract infections (UTIs), bloodstream infections, and pneumonia, and the growing number of people undergoing different surgical procedures.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:

Breakup by Indication:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

  • The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
  • This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

  • 1.What is the market size for the global hospital acquired disease testing market 2024?
  • 2.What is the global hospital acquired disease testing market growth 2025-2033?
  • 3.What are the global hospital acquired disease testing market drivers?
  • 4.What are the key industry trends in the global hospital acquired disease testing market?
  • 5.What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6.What is the global hospital acquired disease testing market breakup by indication?
  • 7.What are the major regions in the global hospital acquired disease testing market?
  • 8.Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2024
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players